Scott Centea - 19 Jul 2023 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)

Role: SVP/GM, VIT
Signature: /s/ Stephen A. Trowbridge, Attorney in Fact
Issuer symbol: ANGO
Transactions as of: 19 Jul 2023
Net transactions value: $0
Form type: 4
Filing time: 21 Jul 2023, 21:11:19 UTC
Previous filing: 18 Jul 2023
Next filing: 25 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANGO	Common Stock	Award	$0	+10,588	+22%	$0.000000	58,716	19 Jul 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANGO	Performance Right	Award	$0	+21,176		$0.000000	21,176	19 Jul 2023	Common Stock	21,176		Direct	F2
transaction	ANGO	Non-Qualified Stock Option (right to buy)	Award	$0	+21,913		$0.000000	21,913	19 Jul 2023	Common Stock	21,913	$8.92	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The acquisition of 10,588 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 10,588 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.
F2	Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.
F3	These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.